NUVB
Nuvation Bio Inc.
NYSE · Healthcare · Biotechnology · US
$6.81
+0.59%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 169.9M | 62.9M | 7.9M | — | — |
| Cost of Revenue | 10.3M | 8.4M | 7.1M | — | — |
| Gross Profit | 159.6M | 54.5M | 795.0K | — | — |
| Operating Expenses | |||||
| R&D Expense | 128.9M | 115.1M | 524.2M | 71.3M | 87.8M |
| SG&A Expense | 158.6M | 151.6M | 69.2M | 28.5M | 31.9M |
| General & Admin Expense | 79.5M | — | 66.7M | 28.5M | 31.9M |
| Selling & Marketing Expense | 500.0K | — | 2.5M | — | — |
| Other Expenses | 9.8M | 856.0K | — | — | — |
| Total Operating Expenses | 297.2M | 267.5M | 593.4M | 99.8M | 119.7M |
| Cost and Expenses | 307.5M | 276.0M | 600.5M | 99.8M | 119.7M |
| Operating Income (EBIT) | (137.6M) | (213.1M) | (592.6M) | (99.8M) | (119.7M) |
| Non-Operating | |||||
| Interest Income | 21.0M | 21.4M | 27.1M | 24.6M | 7.4M |
| Interest Expense | 26.7M | 13.7M | 341.0K | — | — |
| Net Interest Income | (5.6M) | 7.7M | 26.7M | 24.6M | 7.4M |
| Other Non-Op Income/Expense | (12.2M) | 8.4M | 24.7M | 24.0M | 15.5M |
| Non-Operating Income (excl Interest) | (8.4M) | (22.1M) | (25.0M) | (24.0M) | (15.5M) |
| EBT (Pre-Tax Income) | (149.8M) | (204.6M) | (567.9M) | (75.8M) | (104.2M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (149.8M) | (204.6M) | (567.9M) | (75.8M) | (104.2M) |
| Earnings from Cont. Ops | (149.8M) | (204.6M) | (567.9M) | (75.8M) | (104.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (149.8M) | (204.6M) | (567.9M) | (75.8M) | (104.2M) |
| Per Share | |||||
| Basic EPS | ($0.43) | ($0.60) | ($2.11) | ($0.35) | ($0.48) |
| Diluted EPS | ($0.44) | ($0.60) | ($2.11) | ($0.35) | ($0.48) |
| Revenue Per Share | $0.49 | $0.18 | $0.03 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 348.8M | 341.5M | 268.8M | 218.9M | 216.7M |
| Diluted Shares Outstanding | 348.8M | 341.5M | 268.8M | 218.9M | 216.7M |
| Profitability Metrics | |||||
| EBITDA | (127.0M) | (189.2M) | (566.9M) | (75.6M) | (104.0M) |
| D&A | 2.1M | 1.7M | 683.0K | 222.0K | 199.0K |
| EBIT | (129.2M) | (190.9M) | (567.6M) | (75.8M) | (104.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026